| CTRI Number |
CTRI/2018/03/012707 [Registered on: 21/03/2018] Trial Registered Retrospectively |
| Last Modified On: |
13/02/2018 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug |
| Study Design |
Randomized, Parallel Group Trial |
|
Public Title of Study
|
Comparison of nalbuphine and dexmedetomidine for blunting intubation response |
|
Scientific Title of Study
|
Comparison of nalbuphine and dexmedetomidine for attenuation of haemodynamic response to laryngoscopy and intubation |
| Trial Acronym |
|
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Akanksha Rathore |
| Designation |
Postgraduate Student |
| Affiliation |
University College of Medical Sciences and GTB Hospital |
| Address |
Department of Anaesthesiology UCMS and GTBH Dilshad Garden
North East DELHI 110095 India |
| Phone |
8010121855 |
| Fax |
|
| Email |
aksrathore1810@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Sujata Chaudhary |
| Designation |
Director Professor |
| Affiliation |
University College of Medical Sciences and GTB Hospital |
| Address |
Department of Anaesthesiology UCMS and GTBH Dilshad Garden
North East DELHI 110095 India |
| Phone |
9868399705 |
| Fax |
|
| Email |
sujatac462@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Akanksha Rathore |
| Designation |
Postgraduate Student |
| Affiliation |
University College of Medical Sciences and GTB Hospital |
| Address |
Department of Anaesthesiology UCMS and GTBH Dilshad Garden
North East DELHI 110095 India |
| Phone |
8010121855 |
| Fax |
|
| Email |
aksrathore1810@gmail.com |
|
|
Source of Monetary or Material Support
|
| University College of Medical Sciences and Guru Teg Bahadur Hospital Delhi |
|
|
Primary Sponsor
|
| Name |
University College of Medical Sciences and Guru Teg Bahadur Hospital Delhi |
| Address |
Department of Anaesthesiology UCMS and GTBH Dilshad Garden Delhi |
| Type of Sponsor |
Government medical college |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Akanksha Rathore |
University College of Medical Sciences and Guru Teg Bahadur Hospital Delhi |
Department of Anaesthesiology UCMS and GTBH Dilshad Garden Delhi North East DELHI |
8010121855
aksrathore1810@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee Human Research |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
Patients undergoing elective surgery under general anaesthesia and requiring endotracheal intubation , |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Dexmedetomidine |
Patients will receive 1 µg/kg of dexmedetomidine diluted to 10 ml with 0.9% saline solution over a period of 10 minutes before induction of anaesthesia |
| Intervention |
Nalbuphine |
Patients will receive 0.2 µg/kg of nalbuphine diluted to 10 ml with 0.9% saline solution over a period of 10 minutes before induction of anaesthesia. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
60.00 Year(s) |
| Gender |
Both |
| Details |
1 Patients undergoing elective surgery under general anaesthesia and requiring endotracheal intubation
2 Patients belonging to American Society of Anesthesiologist (ASA) grade I and II
3 Patients of either gender
4 Patients between 18-60 years of age
5 Patients between 40-70 kg of weight
6 Modified Mallampati Grade I and II |
|
| ExclusionCriteria |
| Details |
1 Patient’s refusal
2 Patients with history of allergy to opioids, difficult intubation or sleep apnea
3 Patients with history of cardiovascular, cerebral, renal, hepatic, bronchospastic or endocrine disease or psychiatric disorder.
4 Patients on anti hypertensives, hypnotic or narcotic analgesics
5 Patients with anticipated difficult airway (Modified Mallampatti grade III and IV, thyromental distance <6 cm, mouth opening <3 cm, cervical instability)
6 Full stomach patients, pregnant and lactating females. |
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
|
Blinding/Masking
|
Participant and Investigator Blinded |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Change in heart rate (HR) and systolic blood pressure (SBP) |
Tb: Baseline in OT
Td: After test drug administration over 10 minutes
Tp: After propofol administration
Tv: 3 minutes after vecuronium administration
T0: At the time of intubation
T1: 1 minute after endotracheal intubation
T3: 3 minutes after endotracheal intubation
T5: 5 minutes after endotracheal intubation
T10: 10 minutes after endotracheal intubation
T15: 15 minutes after endotracheal intubation
Thereafter, every 15 minutes till the end of surgery. Upto 24 hrs |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
1 Change in diastolic blood pressure (DBP) and mean arterial pressure (MAP)
2 Side effects of the two study drugs |
Tb: Baseline in OT
Td: After test drug administration over 10 minutes
Tp: After propofol administration
Tv: 3 minutes after vecuronium administration
T0: At the time of intubation
T1: 1 minute after endotracheal intubation
T3: 3 minutes after endotracheal intubation
T5: 5 minutes after endotracheal intubation
T10: 10 minutes after endotracheal intubation
T15: 15 minutes after endotracheal intubation
Thereafter, every 15 minutes till the end of surgery. Upto 24 hrs |
|
|
Target Sample Size
|
Total Sample Size="80" Sample Size from India="80"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
16/12/2016 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Open to Recruitment |
|
Publication Details
|
Not applicable |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
|
|
Brief Summary
|
Rationale: Laryngoscopy and endotracheal intubation is associated with haemodynamic changes which can be fatal to patients with hypertension, cardiac dysfunction, coronary artery disease and cerebrovascular disease. It increases heart rate and blood pressure which can precipitate arrhythmias, myocardial infarction, left ventricular failure, pulmonary oedema and cerebral haemorrhage. Various categories of drugs have been tried to attenuate this haemodynamic response but no ideal agent has been found till date. Recently dexmedetomidine and nalbuphine have been studied for attenuation of this haemodynamic response and have been found to be effective. None of the studies have compared these two drugs so this study is designed to compare nalbuphine and dexmedetomidine for attenuation of haemodynamic response to laryngoscopy and endotracheal intubation. Purpose of study: To compare nalbuphine and dexmedetomidine in blunting intubation response and finding out the better drug with an eye on the side effects encountered. Background of study: The haemodynamic changes occuring in response to laryngoscopy and intubation were first described in 1940 by Reid and Brace.Since then various categories of drugs have been studied to blunt this response in order to provide haemodynamic stability to patients specially cardiac patients.But they all have their own side effects hence the search for an ideal agent continues. Dexmedetomidine is a highly specific alpha-2 adrenergic agonist with sympatholytic properties.Numerous studies have found it effective in blunting intubation response. Nalbuphine is a agonist- antagonist opioid with cardiostable properties and it also has been found effective . Aim: To compare the effects of nalbuphine and dexmedetomidine for attenuation of haemodynamic response to laryngoscopy and intubation. Objectives: 1. To study change in - Heart rate (HR) - Systolic (SBP), diastolic (DBP) and mean (MAP) blood pressure 2. To study side effects and complications of both study drugs. Setting: Department of Anaesthesiology & Critical Care, UCMS & GTBH, Delhi. Study design: Randomised, Double Blind, Comparative study Time frame: November 2016 to April 2018 Sample size: 80 patients (40 patients in each group) Method: Group allocation is by computer-generated random number table, into two equal groups and concealed by sealed envelope. · Group N (n=40): Patients will receive 0.2 µg/kg of nalbuphine diluted to 10 ml with 0.9% saline solution over a period of 10 minutes before induction of anaesthesia. · Group D (n=40): Patients will receive 1 µg/kg of dexmedetomidine diluted to 10 ml with 0.9% saline solution over a period of 10 minutes before induction of anaesthesia. Standard general anaesthesia will be administered to all patients. Haemodynamic response to laryngoscopy and endotracheal intubation will be observed intraoperatively. Postoperatively patients will be observed for any side effects of the study drugs. Statistical analysis: Demographic quantitative data will be analysed by unpaired student t test and qualitative data by Chi square test. A p value of <0.05 will be considered significant. Haemodynamic parameters will be analysed using repeated measure of ANOVA followed by Tukey’s test at 5% level of significance. The side effects of two study drugs will be compared using Chi square/ Fisher exact test. Primary outcome measure: Change in heart rate (HR) and systolic blood pressure (SBP) Secondary outcome measure: · Change in diastolic blood pressure (DBP) and mean arterial pressure (MAP). · Side effects of the two study drugs |